Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 553-558

  Salagierski, Maciej ^a   Mulders, Peter ^b   Schalken, Jack A ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Nomogram; Prostate cancer; Prostate cancer antigen 3

Indexed keywords

MEMBRANE PROTEIN; PROSTATE CANCER GENE 3 PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; URINALYSIS;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOPSY; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; POLAND; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84875909906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hessels D, Klein Gunnewiek JM, van O I, Karthaus HF, van Leenders GJ, van BB, Kiemeney LA, Witjes JA and Schalken JA: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15, 2003.
2. Hessels D and Schalken JA: The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 6: 255-261, 2009.
3. Haese A, de la Taille A, van PH, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP and Schalken JA: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54: 1081-1088, 2008.
4. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H and Groskopf J: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69: 532-535, 2007.
5. Chun FK, de la Taille A, van PH, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW and Haese A: Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol 56: 659-667, 2009.
6. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ and Thompson I:Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 180: 1303-1308, 2008.
7. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS and Rittenhouse H: APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006.
8. Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95: 634-635, 2003.
9. Perdona S, Cavadas V, Di LG, Damiano R, Chiappetta G, Del PP, Franco R, Azzarito G, Scala S, Arra C, De SM and Autorino R: Prostate cancer detection in the grey area of prostate-specific antigen below 10 ng/ml: Head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 59: 81-87, 2011.
10. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de RT, Fisch M, Kil P, Gontero P, Irani J and Chun FK: External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58: 727-732, 2010.
11. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H and Groskopf J: PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587-1592, 2008.